Activated suppressor cell function in severely disabled patients with multiple sclerosis

JP Antel, MS Freedman, S Brodovsky… - Annals of Neurology …, 1989 - Wiley Online Library
JP Antel, MS Freedman, S Brodovsky, GS Francis, P Duquette
Annals of Neurology: Official Journal of the American Neurological …, 1989Wiley Online Library
Defective suppressor cell function has previously been demonstrated in patients with
multiple sclerosis (MS) with progressive disease and moderate degrees of disability. In the
present study activated suppressor cell function was assessed in patients with documented
progressive disease who, at the time of study, had experienced severe disability (Kurtzke
score≥ 6.5) for at least 2 years. We found that mean suppressor levels were significantly
increased in this patient group compared with the suppressor levels in the MS patient group …
Abstract
Defective suppressor cell function has previously been demonstrated in patients with multiple sclerosis (MS) with progressive disease and moderate degrees of disability. In the present study activated suppressor cell function was assessed in patients with documented progressive disease who, at the time of study, had experienced severe disability (Kurtzke score ≥ 6.5) for at least 2 years. We found that mean suppressor levels were significantly increased in this patient group compared with the suppressor levels in the MS patient group with progressive disease but only moderate disability (Kurtzke score of ≤ 6.0 within 2 years of study) (59 ± 8% vs 19 ± 7%, respectively, p < 0.01). The mean value in the latter group was significantly reduced compared with the mean value for normal control subjects (47 ± 4%, p < 0.01), a finding consistent with previous reports. The results of this study indicate that suppressor cell function, as measured by our assay system, need not be defective in MS patients who have become severely disabled from the progressive form of the disease. Whether the patients who are now severely disabled from progressive MS passed through a phase of disease associated with the same suppressor defects as found in the progressive patients currently with moderate disability will remain speculative until long‐term longitudinal studies are performed.
Wiley Online Library